Posttransfusion hepatitis in acute myelogenous leukemia. Effect on survival.
We evaluated retrospectively the clinical outcome of 47 patients with acute myelogenous leukemia who entered an intensive chemoimmunotherapy treatment protocol between January 1975 and July 1978. Remission duration and survival were substantially longer in patients in whom hepatitis developed.
D000293:Adolescent; D000328:Adult; D001219:Aspartate Aminotransferases / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006509:Hepatitis B / Q000209:etiology*; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000188:drug therapy; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D013866:Thioguanine / Q000008:administration & dosage
D003561:Cytarabine; D001219:Aspartate Aminotransferases; D013866:Thioguanine; D003630:Daunorubicin